Chemotherapy for metastatic bladder cancer

Advances in Bladder Cancer Management

Volumn , Issue , 2015, Pages 206-220

  Chism, David ^a   Apolo, Andrea ^a   Milowsky, Matthew ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84956766215     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2217/fmeb2013.13.1     Document Type: Chapter

References (39)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917 (2010).
2. Sternberg CN, Yagoda A, Scher HI et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J. Urol. 133, 403-407(1985).
3. Harker WG, Meyers FJ, Freiha FS et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J. Clin. Oncol. 3, 1463-1470 (1985).
4. Logothetis CJ, Dexeus FH, Chong C et al. Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience. J. Urol. 141, 33-37 (1989).
5. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Oncol. 17, 3173-3181 (1999).
6. Apolo AB, Philips G, Ostrovnaya I, Rosenberg JE, Milowsky MI, Small EJ, Bajorin DF, Halabi S. External validation of prognostic models for overall survival (OS) in patients (pts) with advanced UC (UC) treated with cisplatin-based chemotherapy. J. Clin. Oncol. 30(Suppl.) Abstract 4592 (2012).
7. Bellmunt J, Choueiri TK, Fougeray R et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J. Clin. Oncol. 28, 1850-1855 (2010).
8. Niegisch G, Fimmers R, Siener R et al. Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99). Eur. Urol. 60, 1087-1096 (2011).
9. Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 8, 1050-1055 (1990).
10. Loehrer PJ Sr, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 10, 1066-1073 (1992).
11. Sternberg CN, de Mulder PH, Schornagel JH et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J. Clin. Oncol. 19, 2638-2646 (2001).
12. Sternberg CN, de Mulder P, Schornagel JH et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur. J. Cancer 42, 50-54 (2006).
13. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 18, 3068-3077 (2000).
14. von der Maase H, Andersen L, Crino L et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann. Oncol. 10, 1461-1465 (1999).
15. Kaufman D, Raghavan D, Carducci M et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J. Clin. Oncol. 18, 1921-1927 (2000).
16. Moore MJ, Winquist EW, Murray N et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 17, 2876-2881 (1999).
17. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23, 4602-4608 (2005).
18. Bamias A, Dafni U, Karadimou A et al. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Ann. Oncol. 24(4), 1011-1017 (2012).
19. Galsky MD, Hahn NM, Powles T et al. Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin. Genitourin Cancer 11(2), 175-181 (2012).
20. Bellmunt J, von der Maase H, Mead GM et al. Randomized phase III study comparing paclitaxel/cisplatin/ gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J. Clin. Oncol. 30, 1107-1113 (2012).
21. Hahn NM, Stadler WM, Zon RT et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J. Clin. Oncol. 29, 1525-1530 (2011).
22. Tinker A, Winquist E, Canil C et al. A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer. Am. J. Clin. Oncol. 29, 3-7 (2006).
23. Bellmunt J, Guillem V, Paz-Ares L et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J. Clin. Oncol. 18, 3247-3255 (2000).
24. Galsky MD, Hahn NM, Rosenberg J et al. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J. Clin. Oncol. 29, 2432-2438 (2011).
25. Agrawal Y, Platz EA, Niparko JK. Prevalence of hearing loss and differences by demographic characteristics among US adults: data from the National Health and Nutrition Examination Survey, 1999-2004. Arch. Intern. Med. 168, 1522-1530 (2008).
26. Inzitari M, Carlo A, Baldereschi M et al. Risk and predictors of motor-performance decline in a normally functioning population-based sample of elderly subjects: the Italian Longitudinal Study on Aging. J. Am. Geriatr. Soc. 54, 318-324 (2006).
27. Morales-Barrera R, Bellmunt J, Suarez C et al. Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. Eur. J. Cancer 48, 1816-1821 (2012).
28. Hussain SA, Stocken DD, Riley P et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br. J. Cancer 91, 844-849 (2004).
29. Bellmunt J, Ribas A, Eres N et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80, 1966-1972 (1997).
30. Dogliotti L, Carteni G, Siena S et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur. Urol. 52, 134-141 (2007).
31. De Santis M, Bellmunt J, Mead G et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/ vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J. Clin. Oncol. 30, 191-199 (2012).
32. Culine S, Theodore C, De Santis M et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br. J. Cancer 94, 1395-1401 (2006).
33. Vaughn DJ, Srinivas S, Stadler WM et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 115, 4110-4117 (2009).
34. Bellmunt J, Theodore C, Demkov T et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. 27, 4454-4461 (2009).
35. Albers P, Park SI, Niegisch G et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann. Oncol. 22, 288-294 (2011).
36. Sridhar SS, Canil CM, Mukherjee SD et al. Results of a phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma. J. Clin. Oncol. 7(Suppl.), Abstract 241 (2011).
37. Sweeney CJ, Roth BJ, Kabbinavar FF et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J. Clin. Oncol. 24, 3451-3457 (2006).
38. Joly F, Houede N, Noal S et al. Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study. Clin. Genitourin Cancer 7, E28-E33 (2009).
39. Wong YN, Litwin S, Vaughn D et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J. Clin. Oncol. 30, 3545-3551 (2012).